Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
P G RoseM Rodriguez

Abstract

The combination of paclitaxel and a platinum compound is the most active first-line regimen for advanced ovarian carcinoma. The current study was undertaken to evaluate this combination in the re-treatment of patients with ovarian or peritoneal carcinoma who had disease recurrence > or = 6 months following this combination. Twenty-five patients with recurrent ovarian or peritoneal carcinoma > or = 6 months after a complete clinical response with first-line paclitaxel and platinum chemotherapy were studied. Recurrent disease was documented by computed tomography (CT), elevated CA 125 level, or surgical findings. Second-line chemotherapy consisted of paclitaxel 135 mg/m2 as a 24 hour infusion and carboplatin at an area under the concentration-time curve (AUC) of 5 to 6 every 21 days. Response to therapy was classified as measurable or assessable. The median time to recurrence after first-line therapy was 10 months (range, 6 to 30). Among 20 measurable and assessable patients, 14 (70%) demonstrated a complete clinical response and four (20%) a partial clinical response. The response rate with measurable disease was 91% and with assessable disease was 89%. The median progression-free interval for all patients was 9.0+ months (range...Continue Reading

Citations

Aug 10, 2000·The Journal of Obstetrics and Gynaecology Research·S ShamsunderV Kochupillai
Aug 30, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E BriasoulisN Pavlidis
Jun 12, 2002·Current Treatment Options in Oncology·Martee L Hensley
Jul 31, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Maurie MarkmanJerome Belinson
Jan 15, 2016·Acta Biochimica Et Biophysica Sinica·Mingo M H YungDavid W Chan
Apr 7, 2016·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Michelle M BoisenRobert P Edwards
Nov 4, 2017·Future Oncology·Kathleen N MooreMichael J Birrer
Mar 8, 2000·The Oncologist·M Markman, M A Bookman
Aug 7, 2003·American Journal of Clinical Oncology·Shonda Davis-PerryRachel Shank
Apr 21, 2005·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·R F Ozols
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stephen A Cannistra
Jan 27, 2005·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·A KikuchiT Yamamoto
Jun 22, 2007·International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists·Kyoko OtaNobuo Yaegashi
Mar 17, 2007·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·A L LeiserC Aghajanian
Feb 19, 2008·Expert Review of Anticancer Therapy·Maurie Markman
Dec 4, 2009·Expert Review of Anticancer Therapy·Federica TomaoSilverio Tomao
Aug 5, 2011·Journal of the National Cancer Institute·Xiao-Feng LeRobert C Bast
Jan 13, 2010·Journal of Oncology·Kimio Ushijima
Feb 12, 2013·Expert Opinion on Investigational Drugs·Ivy Wilkinson-Ryan, David Mutch
Jun 2, 2018·Future Oncology·Josee-Lyne EthierAmit M Oza
Jun 9, 2001·The Journal of Obstetrics and Gynaecology Research·P J DiSaia, K S Tewari
Mar 10, 2001·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·E. LorenzG. Gundersen
Feb 2, 2002·Current Oncology Reports·Prema P Peethambaram, Harry J Long
Aug 23, 2002·Current Opinion in Oncology·Emery SalomRamin Mirhashemi
Jan 1, 2006·Women's Health·Gamal H Eltabbakh, Scott Goodrich
Nov 26, 2010·Cancer·Ivan N ZamaBrian I Rini
Feb 1, 2019·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·Saul Eugene RivkinErin D Ellis
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Don S DizonDavid R Spriggs
Jan 29, 2011·Cancer Control : Journal of the Moffitt Cancer Center·Gregory P Sfakianos, Laura J Havrilesky
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert F Ozols
Dec 6, 2003·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·A González-Martín, UNKNOWN Geico Group
Feb 1, 2006·International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society·H UtsunomiyaN Yaegashi
Oct 4, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stanley B KayeJosina C Reddy
Apr 14, 2009·Gynecologic Oncology·David M GershensonJohn J Kavanagh
Feb 16, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E AndreopoulouF Muggia

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.